Cushingoid features steroids

One of the commonest causes of Cushing syndrome is the administration of "cortisol-like medications" for the treatment of diverse diseases. All other cases of Cushing syndrome are due to the excess production of cortisol by the adrenal gland as, for example, due to:

  1. An abnormal growth of the pituitary gland, which can stimulate the adrenal gland;
  2. A benign or malignant growth within the adrenal gland itself, which produces cortisol; or
  3. Production within another part of the body (ectopic production) of a hormone that directly or indirectly stimulates the adrenal gland to make cortisol.
The neurosurgeon Harvey Cushing (1869-1939) described excessive production of cortisol by the adrenal gland due specifically to an ACTH-secreting pituitary adenoma, a benign pituitary tumor that puts out ACTH (AdrenoCorticoTropic Hormone). This drives the adrenal gland to overproduce cortisol.

The symptoms and signs of Cushing's syndrome result directly from chronic exposure to excess glucocorticoid. Establishing the diagnosis is often difficult because few of the symptoms or signs are pathognomonic of the syndrome in isolation. There is a large spectrum of manifestations from subclinical to overt syndrome, depending on duration and intensity of excess steroid production. Furthermore, some of them (such as obesity, hypertension, and glucose intolerance) are common in individuals who do not have adrenal hyperfunction. An important clinical clue to the presence of glucocorticoid excess is the simultaneous development and increasing severity of several of these symptoms.

In those patients not suited for or unwilling to undergo surgery, several drugs have been found to inhibit cortisol synthesis (. ketoconazole , metyrapone ) but they are of limited efficacy. [ citation needed ] Mifepristone is a powerful glucocorticoid type II receptor antagonist and, since it does not interfere with normal cortisol homeostatis type I receptor transmission, may be especially useful for treating the cognitive effects of Cushing's syndrome. [38] However, the medication faces considerable controversy due to its use as an abortifacient . In February 2012, the FDA approved mifepristone to control high blood sugar levels ( hyperglycemia ) in adult patients who are not candidates for surgery, or who did not respond to prior surgery, with the warning that mifepristone should never be used by pregnant women. [39]

Cushingoid features steroids

cushingoid features steroids


cushingoid features steroidscushingoid features steroidscushingoid features steroidscushingoid features steroidscushingoid features steroids